MXC: $0.027
What We Believe

We believe that Phytomedicine will effectively treat previously unmet medical needs and improve the lives of patients, impacting public health across the world.

MGC embraces this by creating Phytocannabinoid-based medicine products and providing them in targeted markets. These products are registered for sale and leverage the Company’s own proprietary medical cannabis formula through clinical trials in Europe, Israel and Australia. In addition, tertiary and supplementary revenue streams solidify our presence in the market.

This enables future medical product sales across the European Union, Australia, and other geographies, following the requisite legal and regulatory approvals.

Our Vision

To be a global leader in Phytocannabinoid-based medicines within the biopharmaceutical industry.

MGC Pharma’s goal is to facilitate the transformation of Phytocannabinoids into true medicinal product pipelines, and to provide breakthrough solutions for prevalent global health issues to improve the quality of patients’ lives and contribute to improved public health. MGC Pharma aims to build a responsible and profitable industry.

Our Mission

To Build an Innovative, Vertically Integrated bio-pharma company providing Standardised, Affordable Phytocannabinoid Derived Medicines of the Highest Regulatory Compliance for Targeted global markets and patients

ASX: MXC
$0.027
Sunday, 17 January 2021
Latest Announcements
13/1/21Key Appointment - Global Chief Sales Officer 22/12/20Appendix 2A 22/12/20MGC Pharma to receive grant for Malta production facility 15/12/20ArtemiC Phase II Clinical Trial Results 11/12/20Appendix 2A 9/12/20Completion of Unmarketable Parcel Share Sale Facility 7/12/20ArtemiC Phase II Clinical Trial Results Update

Australia
Pharma Corporate & Financial Headquarters
Slovenia
Pharma European Operational Headquarters
UK
European Corporate Headquarters
Who
What
Why
Contact Us